Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor

Publisher： Bentham Science Publishers

E-ISSN： 1875-6913|9|2|94-101

ISSN： 1875-6921

Source： Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol.9, Iss.2, 2011-06, pp. : 94-101

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metoclopramide/prochlorperazine/trifluoperazine: Tardive dyskinesia with tardive gait: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1197, 2008-01 ,pp. : 31-32

Adis International

Access to resources Recommend Favorite

Ethical considerations for pharmacogenomic testing in pediatric clinical care and research

By Moran Cassandra   Thornburg Courtney D   Barfield Raymond C  

Pharmacogenomics, Vol. 12, Iss. 6, 2011-06 ,pp. : 889-895

Future Medicine

Access to resources Recommend Favorite

Haloperidol: Tardive dyskinesia?: case report

By  

Reactions Weekly, Vol. 1, Iss. 1391, 2012-01 ,pp. : 23-24

Adis International

Access to resources Recommend Favorite

Haloperidol: Tardive dyskinesia in elderly patients, treated with aripiprazole: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1314, 2010-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Risperidone: Tardive dyskinesia: case report

By  

Reactions Weekly, Vol. 1, Iss. 1251, 2009-01 ,pp. : 30-30

Adis International

Access to resources Recommend Favorite